Today, Hikma is a leading pharmaceutical manufacturer with a broad portfolio of generic, branded generic and in-licensed patented products. Our products are sold in over 50 countries and span a broad range of delivery forms and therapeutic areas. The diversity of our business model, our markets and our product portfolio, combined with our long-term commitment to investing in quality, are integral to our success.

We are performing well in the MENA region, particularly in key markets like Egypt and Saudi Arabia. In the US, we are continuing to expand our global Injectables business. The acquisition of Bedford Laboratories in 2014 marks another significant step towards achieving our ambitions in Injectables, enabling Hikma to have the broadest portfolio of generic injectable products in the US and meaningfully enhancing our R&D capabilities. In our oral generics business, we have successfully brought the Eatontown facility back into compliance. The investments we have made to complete the remediation work and strengthen our operations reflect our commitment to quality and are the result of a collaborative global effort.